US008431163B2
`
`(12) United States Patent
`Baldassarre et a].
`
`(10) Patent N0.:
`(45) Date of Patent:
`
`US 8,431,163 B2
`*Apr. 30, 2013
`
`(54)
`
`METHODS OF REDUCING THE RISK OF
`OCCURRENCE OF PULMONARY EDEMA
`ASSOCIATED WITH INHALATION OF
`NITRIC OXIDE GAS
`
`(71)
`
`Applicant: INO Therapeutics LLC, Hampton, NJ
`(Us)
`
`(72)
`
`Inventors: James S. Baldassarre, Doylestown, PA
`(US); Ralf Rosskamp, Chester, NJ (US)
`
`(73)
`
`Assignee: INO Therapeutics LLC, Hampton, NJ
`(Us)
`
`Notice:
`
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`USC 154(b) by 0 days.
`This patent is subject to a terminal dis
`claimer.
`
`(21)
`
`Appl. No.: 13/651,660
`
`(22)
`
`Filed:
`
`Oct. 15, 2012
`
`(65)
`
`(63)
`
`(51)
`
`(52)
`
`(58)
`
`(56)
`
`Prior Publication Data
`
`US 2013/0040000 A1
`
`Feb. 14, 2013
`
`Related US. Application Data
`
`Continuation of application No. 12/ 821,041, ?led on
`Jun. 22, 2010, now Pat. No. 8,293,284, which is a
`continuation of application No. 12/494,598, ?led on
`Jun. 30, 2009, now abandoned.
`
`Int. Cl.
`A01N 59/00
`A61K 33/00
`C01B 21/24
`A61M 16/00
`US. Cl.
`USPC ..................... .. 424/718; 128/200.24; 423/405
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Field of Classi?cation Search ...................... .. None
`See application ?le for complete search history.
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`5,558,083 A
`9/1996 Bathe et al.
`5,651,358 A
`7/1997 Briend et al.
`5,873,359 A
`2/1999 Zapol et al.
`6,063,407 A
`5/2000 Zapol et al.
`6,142,147 A 11/2000 Head et al.
`6,601,580 B1
`8/2003 Bloch et al.
`7,557,087 B2
`7/2009 Rothbard et al.
`2002/0185126 A1 12/2002 Krebs
`2003/0131848 A1
`7/2003 StenZler
`2004/0106954 A1
`6/2004 Whitehurst et al.
`2009/0018136 A1
`1/2009 Oppenheimer et al.
`2009/0029371 A1
`1/2009 Elliott
`2009/0149541 A1
`6/2009 Stark et al.
`2009/0176772 A1
`7/2009 Blackburn et al.
`
`EP
`WO
`WO
`WO
`
`FOREIGN PATENT DOCUMENTS
`1682672
`7/2006
`W02005004884
`1/2005
`W02006127907
`11/2006
`W02010019540
`2/2010
`OTHER PUBLICATIONS
`Kieler-Jensen et al., “Inhaled nitric oxide in the evaluation of heart
`transplant candidates with elevated pulmonary vascular resistance”,
`J. Heart Lung Transplant, vol. 13, pp. 366-375 (1994).
`Kinsella et al., “Inhaled nitric oxide in premature neonates with
`severe hypoxaemic respiratory faliure: a randomised controlled
`trial,” The Lancet, vol. 354, pp. 1061-1065 (1999).
`Konduri et al., “A Randomized Trial of EarlyVersus Standard Inhaled
`Nitric Oxide Therapy in Term and Near-Term Newborn Infants with
`Hypoxic Respiratory Failure,” Pediatrics, vol. 113 No. 3, pp. 559-564
`(2004).
`Krasuski et al., “Inhaled Nitric Oxide Selectively Dilates Pulmonary
`Vasculature in Adult Patients With Pulmonary Hypertension, Irre
`spective of Etiology,” Journal of the American College of Cardiology
`(JACC), vol. 36, No. 7, pp. 2204-2211 (2000).
`Krohn, “Effect of inhaled nitric oxide on left ventricular and pulmo
`nary vascular function,” The Journal of Thoracic and Cardiovascular
`Surgery, vol. 117(1), pp. 195-196 (1999).
`Kulik, “Inhaled nitric oxide in the management of congenital heart
`disease,” Current Opinion in Cardiology, vol. 11, pp. 75-80 (1996).
`Lavigne et al., “Cardiovascular Outcomes of Pediatric Seroreverters
`Perinatally Exposed to HAART,” Cardiovascular Toxicology, vol. 4,
`pp. 187-197 (2004).
`Letter ofAcceptance for AU 2010202422, dated Oct. 7, 2010.
`Letter of acceptance of AU application 2009202685, dated Aug. 10,
`2010, 3 pages.
`LipschultZ, “The effect of dexrazoxane on myocardial injury in
`doxorubicin-treated children with acute lymphoblastic leukemia,”
`New England Journal of Medicine, vol. 351, pp. 145-153 (2004).
`LipschultZ, “The incidence of pediatric cardiomyopathy in two
`regions of the United States,” New England Journal of Medicine, Apr.
`24,
`2003.
`<<http://www.nejm.org/doi/ful1/10.1056/
`NEJMoa021715>>.
`LipshultZ, “Ventricular dysfunction clinical research in infants, chil
`dren and adolescents,” Progress in Pediatric Cardiology, vol. 12, pp.
`1-28 (2000).
`LipshultZ, “Chronic Progressive Cardiac Dysfunction Years After
`Doxorubicin Therapy for Childhood Acute Lymphoblastic Leuke
`mia,” Journal of Clinical Oncology, vol. 23, No. 12, 8 pages (2005).
`LipshultZ, “Clinical research directions in pediatric cardiology,” Cur
`rent Opinion in Pediatrics, vol. 21, pp. 585-593 (2009).
`LipshultZ, “Establishing norms for echocardiographic measurement
`of cardiovascular structures and function in children,” J. Appl.
`Physiol., vol. 99, pp. 386-388 (2005).
`LipshultZ et al., “Cardiovascular status of infants and children of
`women infected with HIV-1 (P2C2 HIV): a cohort study,” The Lan
`cet, vol. 360, pp. 368-373 (2002).
`LipshultZ et al., “Cardiovascular Trials in Long-Term Survivors of
`Childhood Cancer,” Journal ofClinical Oncology, vol. 22, No. 5, pp.
`769-773 (2004).
`LipshultZ et al., “Long-Term Enalapril Therapy for Left Ventricular
`Dysfunction in Doxorubicin-Treated Survivors of Childhood Can
`cer,” Journal of Clinical Oncology, vol. 20, No. 23, pp. 4517-4522
`(2002).
`LipshultZ, “Frequency of clinically unsuspected myocardial injury at
`a children’s hospital,” American Heart Journal, vol. 151, No. 4, pp.
`916-922 (2006).
`
`(Continued)
`Primary Examiner * Ernst Arnold
`(74) Attorney, Agent, or Firm * Fish & Richardson RC.
`(57)
`ABSTRACT
`Disclosed are methods of reducing the risk of occurrence of
`pulmonary edema associated with a medical treatment com
`prising inhalation of nitric oxide gas.
`25 Claims, No Drawings
`
`001
`
`

`
`US 8,431,163 B2
`Page 2
`
`OTHER PUBLICATIONS
`Loh et al ., “Cardiovascular Effects of Inhaled Nitric Oxide in Patients
`With Left Ventricular Dsyfunction,” Circulation, vol. 90, pp. 2780
`2785 (1994).
`Macrae et al., “Inhaled nitric oxide therapy in neonates and children:
`reaching a European consensus,” Intensive Care Med, vol. 30, pp.
`372-380 (2004).
`Madriago et al., “Heart Failure in Infants and Children,” Pediatrics in
`Review, vol. 31, pp. 4-12 (2010).
`Magee et al., “Comparison of Supplemental Oxygen and Nitric
`Oxide for Inhalation plus oxygen in the evaluation of the reactivity of
`the pulmonary vasculature during Acute PulmonaryVasodilator Test
`ing,” Oct. 1, 2004-Oct. 31, 2006, Research project description, 1
`page, http://WWW.rbht.nhs.uldresearch.
`Malloy, “Nitric Oxide Weaning, RT: for Decision Makers in Respi
`ratory Care,” http://rtmagaZine.com/issues/aIticles/2000-12i05.
`asp, 3 pages, Dec. 2000.
`Martinez et al., “Dermatological Cryosurgery in Primary Care With
`Dimethyl Ether Propane Spray in Comparison With Liquid Nitro
`gen,” Atnecion Primaria, vol. 18, No. 5, pp. 211 and 216 (1996).
`Matsumoto et al., “Effect of Inhaled Nitric Oxide on Gas Exchange in
`Patients With Congestive Heart Failure,” Annals of Internal Medicine,
`vol. 130, No. 1, pp. 40-44 (1999).
`Meyler’s Side Effects of Drugs: The International Encyclopedia of
`Adverse Drug Reactions and Interactions, Nitric Oxide, Fifteenth
`Edition, Elsevier B.V. (2006).
`Michelakis et al., “Oral Sildena?l Is an Effective and Speci?c Pul
`monary Vasodilator in Patients With Pulmonary Arterial Hyperten
`sion: Comparison With Inhaled Nitric Oxide,” Circulation vol. 105,
`pp. 2398-2403 (2002).
`Miller et al., “Nutrition in Pediatric Cardiomyopathy,” Prog. Pediatr.
`Cardiol. vol. 24(1), pp. 59-71 (2007).
`Mone, “Effects of Environmental Exposures on the Cardiovascular
`System: Prenatal Period Through Adolescence,” Pediatrics. vol. 1 13,
`No.4, pp. 1058-1069 (2004).
`Morales-Blanhir et al., “Clinical value of vasodilator test With
`inhaled nitric oxide for predicting long-term response to oral
`vasodilators in pulmonary hypertension,” Respiratory Medicine, vol.
`98, pp. 225-234 (2004).
`Moss et al., “Moss and Adams’ Heart Disease in Infants, Children,
`and Adolescents,” Coarctation of the Aorta, vol. 1, p. 991 in part
`(2007).
`Murray, “Angiotensin Converting Enzyme Inhibitory Peptides
`Derived from Food Proteins: Biochemistry, Bioactivity and Produc
`tion,” Current Pharmaceutical Design, pp. 773-791 (2007).
`Murray et al., “Nitric Oxide and Septic Vascular Dysfunction,”
`Anesth. Analg. vol. 90, pp. 89-101 (2000).
`Natori et al., “Inhaled Nitric Oxide Modi?es Left Ventricular Dias
`tolic Stress in the Presence of Vasoactive Agents in Heart Failure,”
`Am. J. Respir Crit. Care Med, vol. 167, pp. 895-901 (2003).
`NIH CC: Critical Care Services, http://WWWcc.nih.gov/ccmd/clini
`caliserviceshtml; retrieved Mar. 10, 2011, 3 pages.
`“NIH Clinical Center 2 Critical Care Medicine Department Sample
`Rotations, Updated Jan. 2007 <<http://WWW.cc.nih.gov/ccmd/profi
`opps/rotation.html>>”.
`NIH Clinical Center Services, retrieved at <http://WWW.cc.nih.gov/
`ccmd/clinicaliservices.html>> on Aug. 18, 2010.
`NIH Clinical Center, Department Policy and Procedure Manual for
`the Critical Care Therapy and Respiratory Care Section; Nitric Oxide
`Therapy, sections 3.1-3.1.2 & 5.2.3 (2000).
`NIH Clinical Center 2 Critical Care Medicine Department Sample
`Rotations, Updated Jan. 2007.
`Noti?cation of Reason for Rejection, mailed Jul. 30, 2010, from
`Japanese Patent Application No. 2009-157623.
`Of?ce Action for AU 2010202422 dated Jul. 9, 2010, 3 pages.
`Of?ce Action from AU 2009202685 dated Mar. 15, 2010.
`Of?ce Action from AU 2010206032 dated Aug. 16, 2010 (3 pages).
`Of?ce Action Response for AU 2009202685 to Mar. 15, 2010 OA,
`?led Jun. 8, 2010 (16 pages).
`Of?ce Action Response for JP2007157623 ?led on Nov. 12, 2009 (no
`English translation).
`Of?ce Action Response to AU 2010202422 OA dated Jul. 9, 2010,
`response ?led Sep. 1, 2010.
`
`WWWfda.gov/doWnloads/Drugs/
`GuidanceComplianceRegulatoryInformation/Guidance/
`ucm073087.pdf, Mar. 1995.
`Of?ce Action in US. Appl. No. 12/494,598, mailed Aug. 13, 2010
`(26 pages).
`Notice ofAbandonment in US. Appl. No. 12/494,598, mailed Sep.
`10, 2010 (2 pages).
`Of?ce Action in US. Appl. No. 12/820,866, mailed Sep. 23, 2010 (26
`pages).
`Lee & Hayes, Reply Amendment (Accelerated Exam-Transmittal
`Amendment/Reply) in US. Appl. No. 12/820,866 mailed Sep. 23,
`2010, ?led Oct. 1, 2010 (22 pages).
`Of?ce Action in US. Appl. No. 12/820,866, mailed Nov. 2, 2010 (25
`pages).
`Lee & Hayes, Reply Amendment (Accelerated Exam-Transmittal
`Amendment/Reply) in US. Appl. No. 12/820,866 mailed Nov. 2,
`2010, ?led Jan. 14, 2011 (12 pages).
`Advisory Action in US. Appl. No. 12/820,866, mailed Feb. 23, 2011
`(2 pages).
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`Amendment/Reply) in US. Appl. No. 12/820,866 mailed Sep. 23,
`2010, ?led Mar. 1, 2011 (9 pages).
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`AmendmentJReply) in US. Appl. No. 12/820,866 mailed Sep. 23,
`2010, ?led Mar. 1, 2011 (5 pages).
`Advisory Action in US. Appl. No. 12/820,866, mailed Mar. 25, 2011
`(3 pages).
`Lee & Hayes, Reply After Final (Accelerated Exam-Transmittal
`AmendmentJReply) in US. Appl. No. 12/820,866 mailed Nov. 2,
`2010, ?led May 2, 2011 (9 pages).
`Of?ce Action in US. Appl. No. 12/820,866, mailed Jun. 8, 2011 (32
`pages).
`Of?ce Action in US. Appl. No. 12/820,866, Aug. 24, 2011 (23
`pages).
`Fish & Richardson, P.C., Reply Brief in US. Appl. No. 12/820,866,
`?led Dec. 16,2011 (21 pages).
`Fish & Richardson, P.C., Supplement to Reply Brief in US. Appl.
`No. 12/820,866, ?led Jan. 3, 2012 (3 pages).
`Of?ce Action in US. Appl. No. 12/820,980, mailed Aug. 17, 2010
`(33 pages).
`Lee & Hayes, Reply Amendment in US. Appl. No. 12/820,980,
`mailed Aug. 17, 2010, ?led Sep. 17, 2010 (25 pages).
`Of?ce Action in US. Appl. No. 12/820,980, mailed Oct. 28, 2010 (23
`pages).
`Supplemental Of?ce Action in US. Appl. No. 12/820,980, mailed
`Nov. 2, 2010 (4 pages).
`Lee & Hayes, Reply after Final (Accelerated Exam-Transmittal
`Reply) in US. Appl. No. 12/820,980, mailed Nov. 2, 2010, ?led Nov.
`12, 2010 (53 pages).
`Advisory Action in US. Appl. No. 12/820,980, mailed Nov. 29, 2010
`(3 pages).
`Lee & Hayes, Reply after Final (Accelerated Exam-Transmittal
`Reply) in US. Appl. No. 12/820,980, mailed Nov. 2, 2010, ?led May
`2,2011 (23 pages).
`Of?ce Action in US. Appl. No. 12/820,980, mailed Jun. 10,2011 (29
`pages).
`Lee & Hayes, Amendment in Reply to Of?ce Action in US. Appl.
`No. 12/820,980, mailed Jun. 10, 201 1, ?ledJul. 11, 2011 (115 pages).
`Of?ce Action in US. Appl. No. 12/820,980, mailed Sep. 9, 2011 (25
`pages).
`Notice of Abandonment in US. Appl. No. 12/820,980, mailed Apr.
`11, 2012 (2 pages).
`Of?ce Action in US. Appl. No. 12/821,020, mailed Aug. 13, 2010
`(24 pages).
`Lee & Hayes, Response to Of?ce Action in US. Appl. No.
`12/821,020, mailed Aug. 13, 2010, ?led Feb. 14,2011 (18 pages).
`Lee & Hayes, Supplemental Reply Amendment in US. Appl. No.
`12/821,020, ?led Apr. 12,2011 (9 pages).
`Of?ce Action in US. Appl. No. 12/821,020, mailed Jun. 27, 2011 (28
`pages).
`Fish & Richardson, P.C., Amendment in Reply to Of?ce Action, in
`US. Appl. No. 12/821,020, mailed Jun. 27, 2011, ?led Dec. 27,2011
`(31 pages).
`
`002
`
`

`
`US 8,431,163 B2
`Page 3
`
`Of?ce Action in U.S.Appl. No. 12/821,020, mailed Jan. 31, 2012 (23
`pages).
`Interview Summary in US. Appl. No. 12/821,020, mailed Apr. 17,
`2012 (4 pages).
`Fish & Richardson, P.C., Statement of Substance of Interview and
`Comments on Examiner’s Interview Summary, in US. Appl. No.
`12/821,020, ?led Apr. 23, 2012 (8 pages).
`Fish & Richardson, PC., Supplemental Amendment, in US. Appl.
`No. 12/821,020, ?led Apr. 30, 2012 (10 pages).
`Of?ce Action in US. Appl. No. 12/821,020, mailed Jun. 15, 2012 (56
`pages).
`Fish & Richardson, P.C., Amendment in Reply, in US. Appl. No.
`12/821,020, mailed Jun. 15, 2012, ?led Aug. 15, 2012 (15 pages).
`Of?ce Action in US. Appl. No. 12/821,041, mailed Aug. 17, 2010
`(32 pages).
`Lee & Hayes, Reply Amendment in US. Appl. No. 12/821,041,
`mailed Aug. 17, 2010, ?led Feb. 14, 2011 (28 pages).
`Lee & Hayes, Supplemental Reply Amendment in US. Appl. No.
`12/821,041, mailed Aug. 17, 2010, ?led Apr. 13,2011 (9 pages).
`Of?ce Action in US. Appl. No. 12/821,041, mailed Jun. 27, 2011 (35
`pages).
`Fish & Richardson, P.C., Amendment in Reply to Of?ce Action in
`US. Appl. No. 12/821,041, mailed Jun. 27, 2011, ?led Jan. 6, 2012
`(155 pages).
`Of?ce Action in US. Appl. No. 12/821,041, mailed Feb. 10, 2012 (36
`pages).
`Fish & Richardson, PC, in US. Appl. No. 12/821,041, Supplemen
`tal Amendment and Remarks, ?led May 11, 2012 (32 pages).
`Of?ce Action in U.S.Appl. No. 12/821,041, mailed Jun. 19, 2012 (61
`pages).
`Fish & Richardson, P.C., Amendment in Reply to Of?ce Action, in
`U.S.Appl.No. 12/821,041,mailedJun. 19,2012,?ledAug. 15,2012
`(17 pages).
`Lee & Hayes Amendment in Reply to Of?ce Action in US. Appl. No.
`12/820,866, mailed Jun. 8, 2011, ?led Jul. 8, 2011 (23 pages).
`Fish & Richardson, Brief on Appeal in US. Appl. No. 12/820,866,
`?led Oct. 4, 2011 (211 pages).
`Interview Summary in US. Appl. No. 12/821,020, mailed Jan. 25,
`2012 (4 pages).
`Ameduri et al., Heart Failure in Children, MED-Continuing Medical
`Education, University of Minnesota. Jul. 29, 2009 (cited Nov. 12,
`2010); available from URL: ttp://www.cme.umn.edu/prod/groups/
`med/@pub/@med/@cme/documents/content/medicontenti
`124593 .pdf.
`Konduri, “Early inhaled nitric oxide therapy for term and near-term
`newborn
`infants
`with
`hypoxic
`respiratory
`failure:
`neurodevelopmental follow-up,” J. Pediatr. vol. 150(3), pp. 235-240,
`240.e.1 (2007).
`Barrington et al., “Inhaled nitric oxide for respiratory failure in
`preterm infants (review),” The Cochrane Collaboration, Wiley Pub
`lishers, 3 pages (2009).
`Barst, Pediatr., “Vasodilator Testing with Nitric Oxide and/ or Oxy
`gen in Pediatric Pulmonary Hypertension,” Cardiol., vol. 31, pp.
`598-606 (2010).
`Macrae, “Drug therapy in persistent pulmonary hypertension of the
`newborn,” Semin. Neonatal, vol. 2, pp. 49-58 (1997).
`Miller et al., “Guidelines for the safe administration of inhaled nitric
`oxide,” Archives of Disease in Childhood, vol. 10, pp. F47-F49
`(1994).
`Ovodov et al., “Nitric Oxide: Clinical Applications,” Seminars in
`Aneshesia, Saunders, CO, NewYork,, NY, vol. 19, No. 2, pp. 88-97
`(2000).
`Pazopanib Plus Lapatinib Compared to Lapatinib Alone in Subjects
`With In?ammatory Breast Cancer, p. 4, ClinicalTrials.gov, <<http://
`clinicaltrials.gov/ct2/show/NCT00558103>> Apr. 22, 2010.
`PCT/US2010/038652 Search Report dated Jul. 29, 2010, 16 pages.
`Pepke-Zaba et al., “Inhaled nitric oxide as a cause of selective pul
`monary vasodilation in pulmonary hypertension,” The Lancet, vol.
`338, pp. 1173-1174 (1991).
`Ratnasamy et al., “Associations between neurohormonal and in?am
`matory activation and heart failure in children,” American Heart
`Journal, pp. 527-533 (2008).
`
`Response ?led Aug. 18, 2010 to EP Search Report dated May 10,
`2010 for EP09251949.
`Ricciardi et al., “Inhaled Nitric Oxide in Primary Pulmonary Hyper
`tension: A Safe and Effective Agent for Predicting Response to
`Nifedipine,” Journal of the American College of Cardiology (JACC)
`vol. 32, No. 4, pp. 1068-1073 (1998).
`Roberts, “Inhaled Nitric Oxide and Persistent Pulmonary Hyperten
`sion of the Newborn,” The New England Journal of Medicine, vol.
`336, No. 9, pp. 605-610 (1997).
`Roberts, “Nitric Oxide and the Lung,” Marcel Dekker, Inc., New
`York, NY, pp. 333-363 (1997).
`Rosales et al., “Hemodynamic Effects Observed with Inhaled Nitric
`OxideAfter Surgical Repair of Total Anamolous Pulmonary Venous
`Return,” Pediatric Cardiology, vol. 20, pp. 224-226 (1999).
`Rosenberg, “Inhaled nitric oxide in the premature infant with severe
`hypoxemic respiratory failure: A time for caution,” The Journal of
`Pediatrics, vol. 133, Issue 6 , pp. 720-722 (1998).
`Sadiq et al., “Inhaled Nitric Oxide in the Treatment of Moderate
`Persistent Pulmonary Hypertension of the Newborn: A Randomized
`Controlled, Multicenter Trial,” Journal of Perinatology, vol. 23, pp.
`98-103 (2003).
`Search Report from EP 09251949 dated May 10, 2010.
`Sehgal et al., “Experience with Inhaled Nitric Oxide Therapy in
`Hypoxic Respiratory Failure of the Newborn,” Indian J. Chest Dis.
`Allied. Sci., vol. 47, pp. 245-249 (2005).
`Semigran et al., “Hemodynamic Effects of Inhaled Nitric Oxide in
`Heart Failure,” Journal of American College of Cardiology (JACC),
`vol. 24, No. 4, pp. 982-988 (1994).
`Shapiro et al., “Diagnostic Dilemmas: Diastolic Heart Failure Caus
`ing Pulmonary Hypertension and Pulmonary Hypertension Causing
`Diastolic Dysfunction,” Advances in Pulmonary Hypertension, vol.
`5(1), pp. 13-20 (2006) http://www.phaonlineuniv.org/sites/default/
`?les/spri2006 .pdf.
`Sibutramine-metformin Combination vs. Sibutramine and Melformin
`Monotherapy in Obese Patients, p. 3, ClinicalTrials.gov, <<http://
`clinicaltrials.gov/ct2/showNCT009413 82>>
`Sponsored
`by
`Laboratorios Silanes SA. de CV. and Jorge Gonzalez Canudas, Jul.
`15, 2009.
`Singh et al., “Nitric Oxide, the biological mediator of the decade: fact
`of ?ction?,” Eur. Respir. J. , vol. 10, pp. 699-707 (1997).
`Smyth, “Inhaled nitric oxide treatment for preterm infants with
`hypoxic respiratory failure,” Thorax, vol. 55 (Suppl 1), pp. S51-S55
`(2000).
`pediatric
`in
`“Exercise rehabilitation
`al.,
`Somarriba et
`cardiomyopathy,” Progress in Pediatric Cardiology, vol. 25, pp.
`91-102 (2008).
`Soto et al., “Cardiopulmonary Hemodynamics in Pulmonary Hyper
`tension: Pressure Tracings, Waveforms, and More,” Advances in
`Pulmonary Hypertension Winter, vol. 7(4), pp. 386-393 (2008).
`Steinhorn et al., “Inhaled nitric oxide enhances oxygenation but not
`survival in infants with alveolar capillary dysplasia,” The Journal of
`Pediatrics, pp. 417-422 (1997).
`Steinhorn, “Persistent Pulmonary Hypertension in the Newborn and
`Infant”, vol. 1(2), pp. 287-299 (1987) [downloadedfrom www.
`Emedicine.com on Jun. 10, 2008.
`Persistent-Newborn”,
`Steinhorn,
`“Pulmonary Hypertension,
`Updated Apr. 19, 2007, http://emedicine.medscape.com/article/
`898437-overview.
`Steudel et al., “Inhaled nitric oxide”, Anesthesiology, vol. 91, pp.
`1090-1121 (1999).
`Strauss et al., “Pediatric CardiomyopathyiA Long Way to Go”, The
`New England Journal of Medicine, vol. 348, No. 17, pp. 1703-1705
`(2003).
`Toshniwal, et al., “Study of Comparative Effects of Oral Clonidine
`vs. Oral Diazepam Pre-Medication on the Extent and Duration of
`Sensory Blockade in Patients Undergoing Vaginal Hysterectomy
`Under Spinal Anaesthesia”, InterenetJournal of Anesthesiology
`(2009)
`<<http://www.britannica.com/bps/additionalcontent/18/
`41575 5 51/Study-of-Comparative-Effects-Oral-Clonidine-vs-Oral
`Diazepam-Pre-Medication-on-the-Extent-and-Duration-of-Sen
`sory-
`Blockade-in-Patients-Undergoing-Vaginal-Hysterectomy
`Under-Spinal-Anaesthesia>>.
`
`003
`
`

`
`US 8,431,163 B2
`Page 4
`
`The American Illustrated Medical Dictionary (Dorland, 7th ed., p.
`1 13) (1914).
`The Effects of Nitric Oxide for Inhalation on the Development of
`Chronic Lung Disease in Pre-Term Infants, from ClinicalTrials.gov
`archive, NCT00551642, Oct. 30, 2007, 3 pages.
`The Encarta Webster’s Dictionary of the English Language (2004) is
`the second edition of the Encarta World Dictionary, published 1999,
`<<http://encarta.msn.com/encnet/features/dictionary/
`dictionaryhome.aspx>>; used to look up the de?nitions of “precau
`tion” and “exclusion”.
`The Neonatal Inhaled Nitric Oxide Study Group, The New England
`Journal of Medicine, vol. 336(9), pp. 597-604 (1997).
`The NIH, Critical Care Therapy and Respiratory Care Section, Nitric
`Oxide Therapy, 13 pages (2000).
`Towbin et al., “Incidence, Causes, and Outcomes of Dilated
`Cardiomyopathy in Children”, JAMA, vol. 296, No. 15, pp. 1867
`1876 (2006).
`The Japanese Of?ce Action mailed Feb. 15, 2011 for Japanese Patent
`Application No. 2009-157623, a counterpart foreign application for
`US. Appl. No. 12/494,598.
`Troncy et al. “Inhaled nitric oxide: clinical applications, indications,
`and toxicology”, Can. J. Anaesth, vol. 44 (9), pp. 972-988 (1997).
`UCI General Clinical Research Center, Federal Regulations 21 CFR
`Part 312, <<http://www.gcrc.uci.edu/rsa/aer.cfm>>, retrieved Sep.
`13, 2010, 2 pages.
`University of Alabama, NCT00732537 at Clinicaltrials. gov (2008).
`“Use of Inhaled Nitric Oxide”, American Academy of Pediatrics
`Committee on Fetus and Newborn, Pediatrics vol. 106, No. 2, pp.
`344-345 (2000).
`UTMB Respiratory Care Services, “Delivery of Inhaled Nitric Oxide
`Therapy through an Adult or Pediatric Nasal Cannula,” 4 pages
`(2003).
`van Dalen, “Treatment for Asymptomatic Anthracycline-Induced
`Cardiac Dysfunction in Childhood Cancer Survivors: The Need for
`Evidence,” Journal of Clinical Oncology, vol. 21, No. 17, pp. 3375
`3379 (2003).
`Watson et al., “Clinical and Economic Effects of iNO in Premature
`Newborns With Respiratory Failure at 1 Year”, Pediatrics, vol. 124,
`pp. 1333-1343 (2009).
`Weinberger et al., “The Toxicology of Inhaled Nitric Oxide,” Toxi
`cological Sciences, vol. 59, pp. 5-16 (2001).
`Weinberger et al., “Nitric Oxide in the lung: therapeutic and cellular
`mechanisms of action,” Pharmacology & Therapeutics, vol. 84, pp.
`401-411 (1999).
`Wessel et al., “Improved Oxygenation in a Randomized Trial of
`Inhaled Nitric Oxide for Persistent Pulmonary Hypertension of the
`Newborn,” Pediatrics, vol. 100, No. 5, p. E7 (1997).
`Wessel et al., “Managing low cardiac output syndrome after congeni
`tal heart surgery,” Crit. Care Med., vol. 29(10) pp. S220-S230 (2001).
`Wheeler et al., “The Central Nervous System in Pediatric Critical
`Illness and Injury,” Pediatric Critical Care Medicine, Springer, p. 278
`(2007).
`Wilkinson et al., “Epidemiological and outcomes research in children
`with pediatric cardiomyopathy; discussions from the international
`workshop on primary and idiopathic cardiomyopathies in children,”
`Progress in Pediatric Cardiology, vol. 25, pp. 23-25 (2008).
`Yoshida, “Well-illustrated Diagnostics and Treatment of Heart Fail
`ure,” Professor of Kawasaki Medical University, cardiovascular
`internal medicine, Circulation, Up-to-Date vol. 2, No. 4, pp. 23-28
`(2007).
`Fish & Richardson P.C., Supplemental Remarks in US. Appl. No.
`12/821,020, ?led May 9, 2012 (22 pages).
`Fish & Richardson P.C., Statement of the Substance of the Interview
`and Comments on Examiner’ s Interview Summary, in US. Appl. No.
`12/821,020, mailed Jan. 25, 2012, ?led Feb. 27, 2012 (7 pages).
`Examiner’s Answer in US. Appl. No. 12/820,866, mailed Nov. 2,
`2011 (27 pages).
`Notice ofAbandonment in US. Appl. No. 12/820,866, mailed Dec.
`20, 2012 (2 pages).
`Adatia et al., “Inhaled Nitric Oxide and Hemodynamic Evaluation of
`Patients With Pulmonary Hyptertension Before Transplantation,”
`Journal of the American College of Cardiology, Elsevier, NewYork,
`NY, vol. 25, No. 7, p. 1663, Jun. 1, 1995.
`
`Advances in Pulmonary Hypertension, vol. 7(4), pp. 1-418, Winter
`2008-2009 (entire issue).
`Al-Alaiyan et al., “Inhaled nitric oxide in persistent pulmonary
`hypertension of the newborn refractory to high-frequency ventila
`tion,” Crit. Care, vol. 3, No. 1, pp. 7-10 (1999).
`ArgenZiano et al., “Inhaled Nitric Oxide is not a Myocardial Depres
`sant in a Porcine Model of Heart Failure,” The Journal of Thoracic
`and Cardiovascular Surgery, vol. 115, pp. 700-704 (1998).
`AtZ et al., “Combined Effects of Nitric Oxide and Oxygen During
`Acute Pulmonary Vasodilator Testing,” Journal of the American Col
`lege of Cardiology (JACC), vol. 33, No. 3, pp. 813-819 (1999).
`AtZ et al., “Inhaled nitric oxide in the neonate with cardiac disease,”
`Seminars in Perinatology, vol. 21(5), pp. 441-455 (1997).
`AU 2009202685 Of?ce Action dated Jun. 17, 2010 (3 pages).
`AU 2009202685 Of?ce Action Response dated Jul. 29, 2010, 19
`pages.
`AZeka et al., “Effects of Low Doses of Inhaled Nitric Oxide Com
`bined with Oxygen for the Evaluation of Pulmonary Vascular Reac
`tivity in Patients with Pulmonary Hypertension,” Pedatric Cardiol.,
`vol. 23, pp. 20-26 (2002).
`Barrington et al., “Inhaled Nitric Oxide for Preterm Infants: A Sys
`tematic Review,” Pediatrics, vol. 120; pp. 1088-1099, DOI: 10.1542/
`peds (2007).
`Barst et al., “Nitric Oxide in Combination with Oxygen versus Either
`Oxygen Alone or Nitric Oxide Alone for Acute Vasodilator Testing in
`Children with Pulmonary Hypertension: A Multicenter, Randomized
`Study,” INO Therapeutic s/Ikaria, Baltimore Convention Center, May
`3, 2009, 2 pages, Abstract, downloaded Jul. 2, 2009 from http://127.
`0.0.1:9080/PAS09A1/view.y?nu:PAS09L1i1507.
`Barst et al., “Vasodilator Testing with Nitric Oxide and/or Oxygen in
`Pediatric Pulmonary Hypertension,” Received: Sep. 14, 2009 /
`Accepted: Jan. 19, 2010 Springer Science+Business Media, LLC
`2010, 9 pages.
`Beggs et al., “Cardiac Failure in Children,” 17th Expert Committee
`on the Selection and Use of Essential Medicines, Geneva, Mar. 2009,
`31 pages.
`Beghetti et al., “Inhaled nitric oxide can cause severe systemic
`hypotension,” Journal of Pediatrics, p. 844 (1997).
`Beghetti et al., “Inhaled nitric oxide and congenital cardiac disease,”
`Cardiol.Young, vol. 11, pp. 142-152 (2001).
`Behera et al., “Nesiritide Improves Hemodynamics in Children with
`Dilated Cardiomyopathy: A Pilot Study,” Pediatr. Cardiol., vol. 30,
`pp. 26-34 (2009).
`Bhagavan et al., “Potential role of ubiquinone (coenZyme Q10) in
`pediatric cardiomyopathy,” Clinical Nutrition, vol. 24, pp. 331-338
`(2005).
`Bichel et al., “Successful weaning from cardiopulmonary bypass
`after cardiac surgery using inhaled nitric oxide”, Pediatric
`Anaesthesia, vol. 7, pp. 335-339 (1997).
`Bin-Nun et al., “Role of iNO in the modulation of pulmonary vascu
`lar resistance,” Journal ofPerinatology, vol. 28, pp. S84-S92 (2008).
`Bland, “Pulmonary vascular dysfuction in preterm lambs with
`chronic lung disease,” Am J Physical Lung Cell Mol. Physiol., vol.
`285: L76-L85 ( 2003).
`Bloch et al., Cardiovasc. Res. 2007, “Inhaled NO as a therapeutic
`agent,” vol. 75(2), pp. 339-348 (Jul. 15, 2007).
`Bocchi et al.,“Inhaled Nitric Oxide Leading to Pulmonary Edema in
`Stable Severe Heart Failure,” The American Journal of Cardiology,
`vol. 74, pp. 70-72 (1994).
`Bolooki, Clinical Application of the Intra-Aortic Balloon Pump, 3rd
`Ed., pp. 252-253 (1998).
`Branson, “Inhaled Nitric Oxide in Adults, The Science Journal of the
`American Association for Respiratory Care 1997 Open Forum
`Abstracts,” Dec. 7, 1997, 2 pages, retrieved at <<http://www.
`rcjournal.com/abstracts/1997/?id:A00000929>> on Dec. 22, 2010.
`Braunwald, Heart Failure, chapter 233 of Harrison’s Principles of
`Internal Medicine, 14th Edition, pp. 1287-1291 and 1360 (1998).
`Bublik et al., Pediatric cardiomyopathy as a chronic disease: A per
`spective on comprehensive care programs, Progress in Pediatric,
`Pediatric Cardiology, vol. 25, pp. 103-111 (2008).
`Budts et al., “Residual pulmonary vasoreactivity to inhaled nitric
`oxide in patients with severe obstructive pulmonary hypertension and
`Eisenmenger syndrome,” Heart, vol. 86, pp. 553-558 (2001).
`
`004
`
`

`
`US 8,431,163 B2
`Page 5
`
`Canadian Of?ce Action mailed May 31, 2011 for Canadian Patent
`Application No. 2671029, a counterpart foreign application of US.
`Appl. No. 12/494,598.
`Clark et al., Low-Dose Nitric Oxide Therapy for Persistent Pulmo
`nary Hypertension: l-Year Follow-up, Journal of Perinatology, vol.
`23, pp. 300-303 (2003).
`Clark et al., “Low-Dose Nitric Oxide Therapy for Persistent Pulmo
`nary Hypertension of the Newborn,” New England Journal of Medi
`cine, vol. 342, No. 7, pp. 469-474 (2000).
`Cockrill et al., “Comparison of the Effects of Nitric Oxide, Nitroprus
`side, and Nifedipine on Hemodynamics and Right Ventricular Con
`tractibility in Patients With Chronic Pulmonary Hypertension,”
`CHEST, vol. 119, No. 1, pp. 128-136 (2001).
`Comparison of Supplemental Oxygen and Nitric Oxide for Inhala
`tion in the Evaluation of the Reactivity of the PulmonaryVasculature
`During Acute Pulmonary Vasodilator Testing, http://clinicaltrials.
`gov/archive/NCTO0626028/2009i01i12 Jan. 12, 2009.
`Corn?eld et al., “Randomized, Controlled Trial of Low-dose Inhaled
`Nitric Oxide in the Treatment of Term and Near-term Infants With
`Respiratory Failure and Pulmonary Hypertension,” Pediatrics, vol.
`104, No. 5, pp. 1089-1094 (1999).
`Cox et al., “Factors Associated with Establishing a Causal Diagnosis
`for Children with Cardiomyopathy,” Pediatrics, vol. 118, No. 4, pp.
`1519-1531 (2006).
`Cujec et al., “Inhaled Nitric Oxide Reduction in Systolic Pulmonary
`Artery Pressure in Less in Patients with Decreased Left Ventricular
`Ejection Fraction,” Canadian Journal of Cardiology, vol. 13(9), pp.
`816-824 (1997).
`Cuthbertson et al., “UK guidelines for the use of inhaled nitric oxide
`therapy in adults ICUs,” Intensive Care Med., vol. 23, Springer
`Verlag, pp. 1212-1218 (1997).
`Davidson et al., “Inhaled nitric oxide for the early treatment of
`persistent pulmonary hypertension of the term newborn: a random
`ized,
`double-masked,
`placebo-controlled,
`dose-response,
`multicenter study,” Pediatrics, vol. 101 (3 Pt 1), pp. 325-34 (1998).
`Davidson et al., “Safety of Withdrawing Inhaled Nitric Oxide
`Therapy in Persistent Pulmonary Hypertension of the Newborn,”
`Pediatrics, vol. 104, No. 2, pp. 231-236 (1999).
`Day et al., “Pulmonary Vasodilatory Effects of 12 and 60 Parts Per
`Million Inhaled Nitric Oxide in Children with Ventricular Septal
`Defect,” The American Journal of Cardiology, vol. 75, pp. 196-198
`(1995).
`De?nition of Contraindication on Medicine.net.com; http://www.
`medterms.com/script/mainfart.asp?articleke}P17824;
`retrieved
`Mar. 14, 2011; 2 pages.
`Delivery of Inhaled Nitric Oxide Therapy through an Adult or Pedi
`atric Nasal Cannula, Reference: UTMB Respiratory Care Services
`Reviewed: May 31, 2005.
`Dickstein et al., “A Theoretic Analysis of the Effect of Pulmonary
`Vasodilation on Pulmonary Venous Pressure: Implications for
`Inhaled Nitric Oxide Therapy,” The Journal of Heart and Lung Trans
`plant, pp. 715-721 (1996).
`Dorland, “The American Illustrated Medical Dictionary,” 7th edition,
`W.B. Saunders Company, p. 113 (1914).
`Dorling, “Neurodevelopmental outcome following Nitric Oxide
`Therapy for Persistent Pulmonary Hypertension in Term Newborn
`Infants,” Neonatal Intensive Care Unit, Leicester Royal In?rmary,
`Aug. 8, 2003, modi?ed Nov. 12, 2003, 3 pages.
`Douwes et al., “The Maze of Vasodilator Response Criteria,” Pub
`lished online: Nov. 26, 2010, Pediatr. Cardiol., vol. 32, pp. 245-246
`(201 1).
`Ehrenkranz, “Inhaled Nitric Oxide in Full-Term and Nearly Full
`Term Infants with Hypoxic Respiratory Failure,” The Neonatal
`Inhaled Nitric Oxide Study Group, N. Engl. J. Med., vol. 336, No. 9,
`pp. 597-605 (1997).
`http://www.cc.nih.gov/ccmd/clinicaliservices.htrnl,
`updated May 19, 2011.
`http://www.medterms.com/script/main/art.asp?articlekey:17824,
`De?nition of Contraindication, last Editorial Revie